The 2006 Sapporo laboratory APS criteria encompass the presence of LA and/or medium-to-high titers of IgM and/or IgG aCL and aß2GPI antibodies detected at two or more occasions at least 12 weeks apart [2]. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.